987 related articles for article (PubMed ID: 17878149)
21. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
Woodis CB
Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
[TBL] [Abstract][Full Text] [Related]
22. Once-yearly zoledronic acid in older men compared with women with recent hip fracture.
Boonen S; Orwoll E; Magaziner J; Colón-Emeric CS; Adachi JD; Bucci-Rechtweg C; Haentjens P; Kaufman JM; Rizzoli R; Vanderschueren D; Claessens F; Sermon A; Witvrouw R; Milisen K; Su G; Lyles KW;
J Am Geriatr Soc; 2011 Nov; 59(11):2084-90. PubMed ID: 22091563
[TBL] [Abstract][Full Text] [Related]
23. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.
Grbic JT; Landesberg R; Lin SQ; Mesenbrink P; Reid IR; Leung PC; Casas N; Recknor CP; Hua Y; Delmas PD; Eriksen EF;
J Am Dent Assoc; 2008 Jan; 139(1):32-40. PubMed ID: 18167382
[TBL] [Abstract][Full Text] [Related]
24. Single annual injectable treatment for postmenopausal osteoporosis.
Chapurlat RD
Expert Opin Drug Deliv; 2008 May; 5(5):583-91. PubMed ID: 18491983
[TBL] [Abstract][Full Text] [Related]
25. Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women.
Lambrinoudaki I; Vlachou S; Galapi F; Papadimitriou D; Papadias K
Clin Interv Aging; 2008; 3(3):445-51. PubMed ID: 18982915
[TBL] [Abstract][Full Text] [Related]
26. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
Reid IR; Brown JP; Burckhardt P; Horowitz Z; Richardson P; Trechsel U; Widmer A; Devogelaer JP; Kaufman JM; Jaeger P; Body JJ; Brandi ML; Broell J; Di Micco R; Genazzani AR; Felsenberg D; Happ J; Hooper MJ; Ittner J; Leb G; Mallmin H; Murray T; Ortolani S; Rubinacci A; Saaf M; Samsioe G; Verbruggen L; Meunier PJ
N Engl J Med; 2002 Feb; 346(9):653-61. PubMed ID: 11870242
[TBL] [Abstract][Full Text] [Related]
27. [Zoledronic acid reduces risk of any new clinical fracture and risk of death after surgical repair of a low-trauma hip fracture].
Leszczyński P
Chir Narzadow Ruchu Ortop Pol; 2010; 75(3):168-71. PubMed ID: 21038635
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial.
Greenspan SL; Perera S; Ferchak MA; Nace DA; Resnick NM
JAMA Intern Med; 2015 Jun; 175(6):913-21. PubMed ID: 25867538
[TBL] [Abstract][Full Text] [Related]
29. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
John Camm A
Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
[TBL] [Abstract][Full Text] [Related]
30. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
Michaelson MD; Kaufman DS; Lee H; McGovern FJ; Kantoff PW; Fallon MA; Finkelstein JS; Smith MR
J Clin Oncol; 2007 Mar; 25(9):1038-42. PubMed ID: 17369566
[TBL] [Abstract][Full Text] [Related]
31. Subgroup variations in bone mineral density response to zoledronic acid after hip fracture.
Magaziner JS; Orwig DL; Lyles KW; Nordsletten L; Boonen S; Adachi JD; Recknor C; Colón-Emeric CS; Mesenbrink P; Bucci-Rechtweg C; Su G; Johnson R; Pieper CF
J Bone Miner Res; 2014 Dec; 29(12):2545-51. PubMed ID: 24839241
[TBL] [Abstract][Full Text] [Related]
32. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial.
McClung M; Miller P; Recknor C; Mesenbrink P; Bucci-Rechtweg C; Benhamou CL
Obstet Gynecol; 2009 Nov; 114(5):999-1007. PubMed ID: 20168099
[TBL] [Abstract][Full Text] [Related]
33. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.
Eastell R; Black DM; Boonen S; Adami S; Felsenberg D; Lippuner K; Cummings SR; Delmas PD; Palermo L; Mesenbrink P; Cauley JA;
J Clin Endocrinol Metab; 2009 Sep; 94(9):3215-25. PubMed ID: 19567517
[TBL] [Abstract][Full Text] [Related]
34. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
35. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial.
Crawford BA; Kam C; Pavlovic J; Byth K; Handelsman DJ; Angus PW; McCaughan GW
Ann Intern Med; 2006 Feb; 144(4):239-48. PubMed ID: 16490909
[TBL] [Abstract][Full Text] [Related]
36. Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial.
Cauley JA; Black D; Boonen S; Cummings SR; Mesenbrink P; Palermo L; Man Z; Hadji P; Reid IR;
J Bone Miner Res; 2011 May; 26(5):984-92. PubMed ID: 21542001
[TBL] [Abstract][Full Text] [Related]
37. Intravenous zoledronic acid for the treatment of osteoporosis.
Lewiecki EM
Curr Osteoporos Rep; 2008 Mar; 6(1):17-23. PubMed ID: 18430396
[TBL] [Abstract][Full Text] [Related]
38. Site-specific differential effects of once-yearly zoledronic acid on the hip assessed with quantitative computed tomography: results from the HORIZON Pivotal Fracture Trial.
Yang L; Sycheva AV; Black DM; Eastell R
Osteoporos Int; 2013 Jan; 24(1):329-38. PubMed ID: 23128664
[TBL] [Abstract][Full Text] [Related]
39. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
Morgan GJ; Davies FE; Gregory WM; Cocks K; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross F; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Child JA;
Lancet; 2010 Dec; 376(9757):1989-99. PubMed ID: 21131037
[TBL] [Abstract][Full Text] [Related]
40. Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?
Cosman F; Cauley JA; Eastell R; Boonen S; Palermo L; Reid IR; Cummings SR; Black DM
J Clin Endocrinol Metab; 2014 Dec; 99(12):4546-54. PubMed ID: 25215556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
